Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hegg

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
ESMO Open|November 26, 2025
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib studyS Kuemmel, K H Jung, L Andrade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)M Martín, A Chan, L Dirix, et al.
ESMO Open|May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialS A Hurvitz, S-B Kim, W-P Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trialP S Schmid, H L McArthur, J Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
ESMO Open|November 26, 2025
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib studyS Kuemmel, K H Jung, L Andrade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)M Martín, A Chan, L Dirix, et al.
ESMO Open|May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialS A Hurvitz, S-B Kim, W-P Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trialP S Schmid, H L McArthur, J Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
Pageof 2